Zobrazeno 1 - 5
of 5
pro vyhledávání: '"L. Kh.-B. Akhmatkhanova"'
Publikováno v:
Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье, Vol 0, Iss 5, Pp 82-87 (2022)
In 19-26% of patients hospitalized with suspected stroke, the cause of neurological symptoms are not cerebrovascular diseases. In this case of newly diagnosed thyrotoxic periodic paralysis we presented the clinical, laboratory and instrumental featur
Externí odkaz:
https://doaj.org/article/4de5a15fa5ca4e29b642447a80642051
Autor:
G. R. Ramazanov, L. Kh.-B. Akhmatkhanova, L. G. Khutsishvili, A. A. Kanibolotskiy, S. S. Petrikov
Publikováno v:
Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье, Vol 0, Iss 4, Pp 62-68 (2022)
Ischemic stroke in oncological diseases occurs as a result of the prothrombotic effect caused by cancer. Besides that, it is associated with antitumor therapy. In the first instance, cardioembolism should be ruled out for recurrent systemic embolism
Externí odkaz:
https://doaj.org/article/f34709e9374444fb9f3f231e70610d01
Autor:
L. Kh.-B. Akhmatkhanova, G. R. Ramazanov, E. V. Klychnikova, R. Sh. Muslimov, M. V. Parkhomenko
Publikováno v:
Неотложная медицинская помощь, Vol 10, Iss 3, Pp 598-603 (2021)
This article reports the first experience of the N.V. Sklifosovsky Research Institute for Emergency Medicine in reperfusion therapy for ischemic stroke in a patient taking oral anticoagulant.
Externí odkaz:
https://doaj.org/article/c2fa7b2adc244968831cde5756f042e6
Autor:
G. R. Ramazanov, E. A. Kovaleva, L. Kh.-B. Akhmatkhanova, A. I. Vyshlova, E. A. Klychnikova, S. S. Petrikov
Publikováno v:
Russian neurological journal. 28:54-61
Dabigatran etexilate (DE) is a direct thrombin inhibitor that has been shown to be eff ective and safe in preventing thrombotic events in a number of studies. Currently idarucizumab, which is a monoclonal antibody and a DE antagonist, is used to imme
Publikováno v:
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 120:56
To assess the efficacy and safety of amantadine sulfate in patients with ischemic stroke.Ninety five patients with ischemic stroke were randomized within 120 hours from the onset of symptoms into two groups: patients of the main group received amanta